Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy

le of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy Review (490) Total Article Views Authors: Flatz L, Conrad C Published Date February 2013 Volume 2013:3 Pages 1 - 10 DOI: http://dx.doi.org/10.2147/PTT.S26339 Received: 21 August 2012 Accepted: 18 December 2012 Published: 27 February 2013 Lukas Flatz, Curdin Conrad Department of Dermatology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland Abstract: Psoriasis is one of the most common chronic, inflammatory, T-cell-mediated autoimmune diseases. Over the past decade, increased knowledge of disease pathogenesis has fundamentally changed psoriasis treatment, with the introduction of biologics, and this has led to a multitude of improved selective targets providing potential therapeutic options. Indeed, numerous pathogenesis-based treatments are currently in development, as psoriasis has also become increasingly relevant for proof-of-concept studies. The purpose of this review was to summarize current knowledge of psoriasis immunopathogenesis, focusing on the T-cell-mediated immune response and its initiation. The authors describe recent advances in psoriasis treatment and discuss pathogenesis-based therapies that are currently in development or which could be envisioned for the future. Although current biologics are well tolerated, several issues such as long-term efficacy, long-term safety, and high costs keep driving the search for new and better therapies. With further advances in understanding disease pathogenesis, more genomic data from psoriasis patients becoming available, and potentially the identification of autoantigens in psoriasis, current research should lead to the development of a growing arsenal of improved targeted treatments and to further breakthrough immunotherapies.